148 related articles for article (PubMed ID: 1679057)
1. Characterization of the individual and cross-reactive antigens involved in the anti-tumor immunity induced by use of an H-2K-erbB recombinant gene transfectant.
Ding LN; Yoshida T; Isobe K; Rahman SM; Nagase F; Yokochi T; Kawashima K; Nakashima I
Jpn J Cancer Res; 1991 Jul; 82(7):841-7. PubMed ID: 1679057
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic T lymphocyte recognition of the H-2-erbB hybrid gene product lacking the complete H-2 domain structure.
Ding L; Isobe K; Iwamoto T; Yoshida T; Nagase F; Kawashima K; Nakashima I
Int Immunol; 1990; 2(1):91-7. PubMed ID: 1708275
[TBL] [Abstract][Full Text] [Related]
3. Induction of high-grade anti-tumor immunity by use of a recombinant H-2Kb/avian erythroblastosis virus erbB gene transfectant.
Ding LN; Isobe K; Yoshida T; Kawashima K; Nakashima I
Cancer Immunol Immunother; 1990; 31(2):115-20. PubMed ID: 2157549
[TBL] [Abstract][Full Text] [Related]
4. Cell-mediated immunity to chemically xenogenized tumors. I. Inhibition by specific antisera and H-2 association of the novel antigens.
Romani L; Grohmann U; Fazioli F; Puccetti P; Mage MG; Fioretti MC
Cancer Immunol Immunother; 1988; 26(1):48-54. PubMed ID: 3257903
[TBL] [Abstract][Full Text] [Related]
5. Induction of antitumor immunity in mice by allo-major histocompatibility complex class I gene transfectant with strong antigen expression.
Isobe K; Hasegawa Y; Iwamoto T; Hasegawa T; Kawashima K; Ding LN; Nakashima I
J Natl Cancer Inst; 1989 Dec; 81(23):1823-8. PubMed ID: 2585529
[TBL] [Abstract][Full Text] [Related]
6. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts.
Nagata Y; Furugen R; Hiasa A; Ikeda H; Ohta N; Furukawa K; Nakamura H; Furukawa K; Kanematsu T; Shiku H
J Immunol; 1997 Aug; 159(3):1336-43. PubMed ID: 9233630
[TBL] [Abstract][Full Text] [Related]
7. Generation of antigenic variants from a nonantigenic murine tumor cell line by transfection with a gene encoding a novel tumor-specific transplantation antigen.
Kaba DS; McIntyre BW; Kripke ML; Goodenow RS; Schreiber H; Ananthaswamy HN
Cancer Res; 1989 Jan; 49(1):38-43. PubMed ID: 2783244
[TBL] [Abstract][Full Text] [Related]
8. Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice.
Kacha AK; Fallarino F; Markiewicz MA; Gajewski TF
J Immunol; 2000 Dec; 165(11):6024-8. PubMed ID: 11086033
[TBL] [Abstract][Full Text] [Related]
9. Identification of a unique tumor-specific antigen as a novel class I major histocompatibility molecule.
Philipps C; McMillan M; Flood PM; Murphy DB; Forman J; Lancki D; Womack JE; Goodenow RS; Schreiber H
Proc Natl Acad Sci U S A; 1985 Aug; 82(15):5140-4. PubMed ID: 3860848
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of T-lymphocyte-mediated tumor-specific lysis by alloantisera directed against the H-2 serological specificities of the tumor.
Germain RN; Dorf ME; Benacerraf B
J Exp Med; 1975 Oct; 142(4):1023-8. PubMed ID: 809532
[TBL] [Abstract][Full Text] [Related]
11. Cell surface expression of cytotoxic T lymphocyte-defined, AKR/Gross leukemia virus-associated tumor antigens by normal AKR.H-2b splenic B cells.
Green WR
J Immunol; 1983 Dec; 131(6):3078-84. PubMed ID: 6605998
[TBL] [Abstract][Full Text] [Related]
12. Cross-reacting antigens on L5178Y cells which serve as targets for cytotoxic T-lymphocyte lysis during establishment of the tumor dormant state.
Weinhold KJ; Wheelock EF
Cancer Res; 1982 Sep; 42(9):3607-16. PubMed ID: 6179603
[TBL] [Abstract][Full Text] [Related]
13. Differential antigenic expression of the DBA/2 lymphoma L1210 and its sublines: cross-reactivity with C3H mammary tumors as defined by syngeneic monoclonal antibodies.
Rapp L; Fuji H
Cancer Res; 1983 Jun; 43(6):2592-9. PubMed ID: 6342755
[TBL] [Abstract][Full Text] [Related]
14. Alloreactivity and tumor antigens: generation of syngeneic antilymphoma killer lymphocytes by alloimmunization of mice with normal cells.
Sensi ML; Parenza M; Parmiani G
J Natl Cancer Inst; 1983 Feb; 70(2):291-7. PubMed ID: 6571938
[TBL] [Abstract][Full Text] [Related]
15. H-2 antigens and tumour-associated transplantation antigens in clones derived from a methylcholanthrene-induced BALB/c tumour: their influence on the generation in vitro and in vivo of the specific anti-tumour immune response.
Pérez M; Garrido A; Algarra I; Caballero A; Delgado C; Collado MD; Fernández-Cruz E; Garrido F
Exp Clin Immunogenet; 1989; 6(3):204-18. PubMed ID: 2631798
[TBL] [Abstract][Full Text] [Related]
16. The blocking activity of antisera raised to either tumor antigens or alloantigens in cytotoxicity assays using syngeneic or allogeneic killer cells on the P815 murine mastocytoma target.
Al-Rammahy AK; Levy JG
Cell Immunol; 1980 Dec; 56(2):338-46. PubMed ID: 6781763
[No Abstract] [Full Text] [Related]
17. Cell surface antigens of murine leukemias induced by radiation leukemia virus. Recognition of individually distinct cell surface antigens by cytotoxic T cells on leukemias expressing crossreactive transplantation antigens.
Morishita H; Shiku H; Horibe K; Obata Y; Stockert E; Oettgen HF; Old LJ; Yamada K
J Exp Med; 1986 Feb; 163(2):452-7. PubMed ID: 3003228
[TBL] [Abstract][Full Text] [Related]
18. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
19. Differential ability of tumor-unique and cross-reactive antigen(s) on two murine hepatoma cell lines to induce Lyt-1+2- T cells responsible for in vivo protective immunity.
Shima J; Yoshioka T; Kosugi A; Ogata M; Fujiwara H; Hamaoka T; Ueda S; Kato S
Biken J; 1987 Mar; 30(1):1-8. PubMed ID: 2445335
[TBL] [Abstract][Full Text] [Related]
20. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
